Standard BioTools Soars 12.26% on Strong Q1 Earnings

On May 7, 2025, Standard BioTools experienced a significant pre-market rise of 12.26%, reflecting strong investor confidence in the company's recent financial performance and strategic initiatives.

Standard BioTools reported a first-quarter 2025 revenue of $40.8 million, surpassing analyst estimates of $40.1 million. The company also demonstrated a 45% reduction in operating loss and a 29% improvement in adjusted EBITDA year-over-year, indicating robust operational efficiency and cost management.

Standard BioTools expects full-year revenue to range between $165 million and $175 million, signaling optimism about its growth prospects. The company's strategic operationalization of $10 million in the first quarter further underscores its commitment to enhancing operational capabilities and driving future growth.